Spago Nanomedical is a Swedish biotechnology company developing products for precision imaging and radionuclide treatment of cancer and other devastating diseases. The company´s two main development programs, SpagoPix and Tumorad, are based on a unique and proprietary platform for physiological accumulation of optimized and functionalized polymeric particles in tumors.
Candidate drug SN132D is a gadolinium-free contrast agent for precision magnetic resonance imaging (MRI) with exceptionally high signal strength. By selective physiological accumulation in tumor tissue, SpagoPix meets a well recognized need for significantly improved soft tissue tumor imaging with further potential in inflammatory endometriosis.
Candidate drug 177Lu-SN201 is a novel radiopharmaceutical nanoprticle with potential to expand the scope of radionuclide therapy in solid tumor indications not currently targetable by other modalities, as monotherapy or in combinations with established treatments.
Company Details
- Employees
- 19
- Founded
- -
- Address
- Scheelevägen 22, Lund,se-223 63,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.spagonanomedical.se
- Keywords
- Nanomedicine for cancer diagnosis and treatment, Drug delivery and PEGylation, MRI contrast agent development.
- HQ
- Lund
Spago Nanomedical Ab Questions
Spago Nanomedical Ab's website is http://www.spagonanomedical.se
Spago Nanomedical Ab's LinkedIn profile is https://se.linkedin.com/company/spago-nanomedical
Spago Nanomedical Ab has
19 employees.
View email and phone details for 19
employees at Spago Nanomedical Ab.
Spago Nanomedical Ab's industry is
Biotechnology Research
Spago Nanomedical Ab's top competitors are
Inceptua Group,
Bioinvent International Ab,
Novo Nordisk,
Initiator Pharma,
Ziccum Ab,
Xvivo,
Västra Hamnen Corporate Finance,
Cyclotek Pty Ltd,
Cytiva,
Region Skåne.
Spago Nanomedical Ab's categories are Biotechnology Research
Spago Nanomedical Ab's founding year is 2007
